XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended Jun...(nds of US dollars except share and per s...)

Period from

Six months ended March 9, 1993(*)

June 30, to June 30,

2007 2006 2007

----------- ----------- -----------

REVENUES:

Reimbursed out-of-pocket expenses -- -- 6,012

License 227 227 1,320

---------- ---------- ---------

227 227 7,332

COST OF REVENUES:

Reimbursed out-of-pocket expenses -- -- 6,012

License (with respect to

royalties) 27 27 167

----------- ----------- ---------

27 27 6,179

GROSS MARGIN 200 200 1,153

----------- ----------- ---------

RESEARCH AND DEVELOPMENT COSTS

(includes non-cash stock option

compensation of $66 and $107,

for the six months ended

June 30, 2007 and 2006,

respectively) 12,118 5,008 105,237

L E S S - PARTICIPATIONS 56 -- 11,006

----------- ----------- ---------

12,062 5,008 94,231

IN-PROCESS RESEARCH AND

DEVELOPMENT COSTS -- -- 1,783

GENERAL AND ADMINISTRATIVE

EXPENSES (includes non-cash

stock option compensation of

$892 an
'/>"/>

SOURCE XTL Biopharmaceuticals Ltd Copyright©2007 PR Newswire.

0 GOOD